1. Medicines
  2. Neuroscience
  3. GILENYA® ▼ (fingolimod)
  4. Resources
  5. The young person’s guide to Gilenya

Prescribing information

 

The young person’s guide to Gilenya

A booklet to help your paediatric patients understand more about their treatment.If you would like to receive copies of any of these materials, please contact your Key Account Manager.

Gd+: gadolinium enhancing; MRI: magnetic resonance imaging; RES: rapidly evolving severe; RRMS: relapsing remitting multiple sclerosis.

Indication: GILENYA is indicated as a single disease modifying therapy in highly active RRMS for the following groups of adult patients and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with ≥1 disease modifying therapy, or patients with RES RRMS defined by ≥2 disabling relapses in 1 year, and with 1 or more Gd+ lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.1

Reference

  1. GILENYA (fingolimod) Summary of Product Characteristics.

Download

GIL19-C053e March 2020.
Neuroscience
Resource
Print
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]